ETC
Exchange Traded Concepts Portfolio holdings
AUM
$7.83B
1-Year Return
24.45%
This Quarter Return
+8.63%
1 Year Return
+24.45%
3 Year Return
+83.69%
5 Year Return
+131.49%
10 Year Return
–
AUM
$3.86B
AUM Growth
+$120M
(+3.2%)
Cap. Flow
-$142M
Cap. Flow
% of AUM
-3.67%
Top 10 Holdings %
Top 10 Hldgs %
15.38%
Holding
1,480
New
255
Increased
503
Reduced
456
Closed
248
Top Buys
| 1 |
JPMorgan Equity Premium Income ETF
JEPI
|
+$55.9M |
| 2 |
Janus Henderson AAA CLO ETF
JAAA
|
+$39.4M |
| 3 |
Technology Select Sector SPDR Fund
XLK
|
+$32.5M |
| 4 |
AT&T
T
|
+$25.9M |
| 5 |
SPDR Nuveen ICE High Yield Municipal Bond ETF
HYMB
|
+$25.8M |
Top Sells
| 1 |
Vanguard Short-Term Bond ETF
BSV
|
+$55.9M |
| 2 |
NVIDIA
NVDA
|
+$46.9M |
| 3 |
Utilities Select Sector SPDR Fund
XLU
|
+$41.2M |
| 4 |
Vanguard Real Estate ETF
VNQ
|
+$38.9M |
| 5 |
Vanguard Long-Term Bond ETF
BLV
|
+$38.5M |
Sector Composition
| 1 | Technology | 24.22% |
| 2 | Energy | 11.31% |
| 3 | Healthcare | 9.73% |
| 4 | Communication Services | 7.59% |
| 5 | Industrials | 7.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
801
Genelux
GNLX
$136M
| $294K | 0.01% |
45,736
+39,535
| +638% | +$254K |
|
802
Arcus Biosciences
RCUS
$1.28B
| $294K | 0.01% |
15,553
+8,737
| +128% | +$165K |
|
803
Houlihan Lokey
HLI
$14.5B
| $293K | 0.01% |
+2,289
| New | +$293K |
|
804
Tractor Supply
TSCO
$31.5B
| $293K | 0.01% |
+5,600
| New | +$293K |
|
805
EastGroup Properties
EGP
$8.8B
| $293K | 0.01% |
1,630
+178
| +12% | +$32K |
|
806
Compass Therapeutics
CMPX
$607M
| $291K | 0.01% |
146,874
+81,055
| +123% | +$160K |
|
807
Apollomics
APLM
$12.8M
| $291K | 0.01% |
3,876
+3,519
| +986% | +$264K |
|
808
Hilton Worldwide
HLT
$65.1B
| $291K | 0.01% |
1,362
+1,157
| +564% | +$247K |
|
809
Kymera Therapeutics
KYMR
$3.24B
| $290K | 0.01% |
7,212
-147
| -2% | -$5.91K |
|
810
Relay Therapeutics
RLAY
$712M
| $289K | 0.01% |
34,876
+19,914
| +133% | +$165K |
|
811
Fate Therapeutics
FATE
$120M
| $289K | 0.01% |
39,410
-24,315
| -38% | -$178K |
|
812
Precigen
PGEN
$1.23B
| $289K | 0.01% |
199,255
+105,164
| +112% | +$152K |
|
|
MOR
813
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $288K | 0.01% |
15,883
-1,554
| -9% | -$28.2K |
|
814
Merus
MRUS
$5.17B
| $288K | 0.01% |
6,389
+636
| +11% | +$28.6K |
|
815
Lyell Immunopharma
LYEL
$249M
| $288K | 0.01% |
6,447
+2,299
| +55% | +$103K |
|
816
Revolution Medicines
RVMD
$8.66B
| $287K | 0.01% |
8,910
-2,372
| -21% | -$76.4K |
|
817
Cullinan Oncology
CGEM
$390M
| $287K | 0.01% |
16,850
+2,774
| +20% | +$47.3K |
|
818
Xencor
XNCR
$617M
| $286K | 0.01% |
12,934
+6,158
| +91% | +$136K |
|
819
HUTCHMED
HCM
$2.79B
| $285K | 0.01% |
16,981
+7,450
| +78% | +$125K |
|
820
Halliburton
HAL
$19.3B
| $285K | 0.01% |
7,230
+7,158
| +9,942% | +$282K |
|
821
Arcellx
ACLX
$4.14B
| $285K | 0.01% |
4,096
-145
| -3% | -$10.1K |
|
|
INBX
822
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $285K | 0.01% |
8,143
+1,438
| +21% | +$50.3K |
|
823
Nasdaq
NDAQ
$54.9B
| $284K | 0.01% |
4,504
+1,427
| +46% | +$90K |
|
824
Janux Therapeutics
JANX
$1.48B
| $284K | 0.01% |
7,544
-6,660
| -47% | -$251K |
|
825
Immuneering
IMRX
$349M
| $284K | 0.01% |
98,254
+80,838
| +464% | +$234K |
|